Do analysts recommend PLYX or TAOX?

Polaryx Therapeutics currently has a consensus target price of $8.50, suggesting a potential upside of 314.63%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Polaryx Therapeutics is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polaryx Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PLYX or TAOX more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Synaptogenix's return on equity. Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A Synaptogenix N/A -163.40% -133.47%

Do analysts rate FTLF or TAOX?

FitLife Brands presently has a consensus price target of $21.50, indicating a potential upside of 109.76%. Given FitLife Brands' stronger consensus rating and higher probable upside, analysts clearly believe FitLife Brands is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FitLife Brands 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, FTLF or TAOX?

FitLife Brands has higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio FitLife Brands $90.85M 1.06 $6.33M $0.60 17.08 Synaptogenix $687.84K 35.74 -$28.74M -$13.28 N/A

Do analysts prefer ALDX or TAOX?

Aldeyra Therapeutics presently has a consensus price target of $5.50, indicating a potential upside of 261.84%. Given Aldeyra Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Aldeyra Therapeutics is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aldeyra Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ALDX or TAOX more profitable?

Aldeyra Therapeutics' return on equity of -57.34% beat Synaptogenix's return on equity. Company Net Margins Return on Equity Return on Assets Aldeyra Therapeutics N/A -57.34% -36.33% Synaptogenix N/A -163.40% -133.47%

Do analysts prefer TAOX or BDTX?

Black Diamond Therapeutics has a consensus price target of $9.83, indicating a potential upside of 458.71%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Black Diamond Therapeutics 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.73

Is TAOX or BDTX more profitable?

Black Diamond Therapeutics' return on equity of -30.18% beat Synaptogenix's return on equity. Company Net Margins Return on Equity Return on Assets Synaptogenix N/A -163.40% -133.47% Black Diamond Therapeutics N/A -30.18% -23.91%

Do analysts prefer ICCC or TAOX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, ICCC or TAOX?

ImmuCell has higher revenue and earnings than Synaptogenix. ImmuCell is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmuCell $27.64M 3.61 -$1.04M -$0.06 N/A Synaptogenix $687.84K 35.74 -$28.74M -$13.28 N/A

Is ICCC or TAOX more profitable?

Synaptogenix has a net margin of 0.00% compared to ImmuCell's net margin of -1.82%. ImmuCell's return on equity of -1.88% beat Synaptogenix's return on equity. Company Net Margins Return on Equity Return on Assets ImmuCell -1.82% -1.88% -1.22% Synaptogenix N/A -163.40% -133.47%

Synaptogenix (TAOX) Competitors

$3.29 -0.38 (-10.35%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$3.38 +0.09 (+2.74%)

As of 07/24/2026 07:34 PM Eastern

Compare

TAOX vs. PLYX, FTLF, ALDX, BDTX, and ICCC

Should you buy Synaptogenix stock or one of its competitors? MarketBeat compares Synaptogenix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Synaptogenix include Polaryx Therapeutics (PLYX), FitLife Brands (FTLF), Aldeyra Therapeutics (ALDX), Black Diamond Therapeutics (BDTX), and ImmuCell (ICCC). These companies are all part of the "pharmaceutical products" industry.

How does Synaptogenix compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and Synaptogenix (NASDAQ:TAOX) are both small-cap manufacturing companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

10.3% of Synaptogenix shares are held by institutional investors. 2.7% of Synaptogenix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Polaryx Therapeutics' return on equity of 0.00% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Synaptogenix	N/A	-163.40%	-133.47%

Polaryx Therapeutics currently has a consensus target price of $8.50, suggesting a potential upside of 314.63%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Polaryx Therapeutics is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Polaryx Therapeutics has higher earnings, but lower revenue than Synaptogenix. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	N/A	-$0.05	N/A
Synaptogenix	$687.84K	35.74	-$28.74M	-$13.28	N/A

In the previous week, Polaryx Therapeutics had 1 more articles in the media than Synaptogenix. MarketBeat recorded 2 mentions for Polaryx Therapeutics and 1 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 1.87 beat Polaryx Therapeutics' score of 0.31 indicating that Synaptogenix is being referred to more favorably in the news media.

Company	Overall Sentiment
Polaryx Therapeutics	Neutral
Synaptogenix	Very Positive

Summary

Polaryx Therapeutics beats Synaptogenix on 7 of the 12 factors compared between the two stocks.

How does Synaptogenix compare to FitLife Brands?

FitLife Brands (NASDAQ:FTLF) and Synaptogenix (NASDAQ:TAOX) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

FitLife Brands presently has a consensus price target of $21.50, indicating a potential upside of 109.76%. Given FitLife Brands' stronger consensus rating and higher probable upside, analysts clearly believe FitLife Brands is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FitLife Brands	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

FitLife Brands has a net margin of 6.64% compared to Synaptogenix's net margin of 0.00%. FitLife Brands' return on equity of 18.31% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FitLife Brands	6.64%	18.31%	8.21%
Synaptogenix	N/A	-163.40%	-133.47%

In the previous week, FitLife Brands and FitLife Brands both had 1 articles in the media. FitLife Brands' average media sentiment score of 1.87 equaled Synaptogenix'saverage media sentiment score.

Company	Overall Sentiment
FitLife Brands	Very Positive
Synaptogenix	Very Positive

FitLife Brands has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market.

FitLife Brands has higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FitLife Brands	$90.85M	1.06	$6.33M	$0.60	17.08
Synaptogenix	$687.84K	35.74	-$28.74M	-$13.28	N/A

2.3% of FitLife Brands shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 61.7% of FitLife Brands shares are held by company insiders. Comparatively, 2.7% of Synaptogenix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

FitLife Brands beats Synaptogenix on 11 of the 14 factors compared between the two stocks.

How does Synaptogenix compare to Aldeyra Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Synaptogenix (NASDAQ:TAOX) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

Aldeyra Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market.

Aldeyra Therapeutics' return on equity of -57.34% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-57.34%	-36.33%
Synaptogenix	N/A	-163.40%	-133.47%

In the previous week, Aldeyra Therapeutics had 1 more articles in the media than Synaptogenix. MarketBeat recorded 2 mentions for Aldeyra Therapeutics and 1 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 1.87 beat Aldeyra Therapeutics' score of 1.44 indicating that Synaptogenix is being referred to more favorably in the news media.

Company	Overall Sentiment
Aldeyra Therapeutics	Positive
Synaptogenix	Very Positive

59.7% of Aldeyra Therapeutics shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 11.8% of Aldeyra Therapeutics shares are held by company insiders. Comparatively, 2.7% of Synaptogenix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Aldeyra Therapeutics presently has a consensus price target of $5.50, indicating a potential upside of 261.84%. Given Aldeyra Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Aldeyra Therapeutics is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Synaptogenix has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A
Synaptogenix	$687.84K	35.74	-$28.74M	-$13.28	N/A

Summary

Aldeyra Therapeutics beats Synaptogenix on 9 of the 14 factors compared between the two stocks.

How does Synaptogenix compare to Black Diamond Therapeutics?

Synaptogenix (NASDAQ:TAOX) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

Synaptogenix has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.25, meaning that its stock price is 225% more volatile than the broader market.

In the previous week, Black Diamond Therapeutics had 2 more articles in the media than Synaptogenix. MarketBeat recorded 3 mentions for Black Diamond Therapeutics and 1 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 1.87 beat Black Diamond Therapeutics' score of 1.46 indicating that Synaptogenix is being referred to more favorably in the media.

Company	Overall Sentiment
Synaptogenix	Very Positive
Black Diamond Therapeutics	Positive

Black Diamond Therapeutics has lower revenue, but higher earnings than Synaptogenix. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$687.84K	35.74	-$28.74M	-$13.28	N/A
Black Diamond Therapeutics	N/A	N/A	$22.37M	-$0.77	N/A

Black Diamond Therapeutics has a consensus price target of $9.83, indicating a potential upside of 458.71%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

Black Diamond Therapeutics' return on equity of -30.18% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-163.40%	-133.47%
Black Diamond Therapeutics	N/A	-30.18%	-23.91%

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Black Diamond Therapeutics beats Synaptogenix on 12 of the 15 factors compared between the two stocks.

How does Synaptogenix compare to ImmuCell?

ImmuCell (NASDAQ:ICCC) and Synaptogenix (NASDAQ:TAOX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

13.5% of ImmuCell shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 5.7% of ImmuCell shares are held by company insiders. Comparatively, 2.7% of Synaptogenix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

ImmuCell has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Synaptogenix has a net margin of 0.00% compared to ImmuCell's net margin of -1.82%. ImmuCell's return on equity of -1.88% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	-1.82%	-1.88%	-1.22%
Synaptogenix	N/A	-163.40%	-133.47%

ImmuCell has higher revenue and earnings than Synaptogenix. ImmuCell is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.61	-$1.04M	-$0.06	N/A
Synaptogenix	$687.84K	35.74	-$28.74M	-$13.28	N/A

In the previous week, ImmuCell had 4 more articles in the media than Synaptogenix. MarketBeat recorded 5 mentions for ImmuCell and 1 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 1.87 beat ImmuCell's score of 1.08 indicating that Synaptogenix is being referred to more favorably in the news media.

Company	Overall Sentiment
ImmuCell	Positive
Synaptogenix	Very Positive

Summary

ImmuCell beats Synaptogenix on 8 of the 13 factors compared between the two stocks.

Get Synaptogenix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TAOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TAOX vs. The Competition

Export

Metric	Synaptogenix	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$24.58M	$975.11M	$7.24B	$12.25B
Dividend Yield	N/A	4.84%	40.99%	9.79%
P/E Ratio	-0.25	1.53	23.62	23.64
Price / Sales	35.74	105.75	133.23	89.03
Price / Cash	N/A	20.06	165.01	59.64
Price / Book	1.16	8.47	12.77	6.07
Net Income	-$28.74M	-$2.70M	$120.21M	$331.99M
7 Day Performance	-4.91%	-2.29%	-0.98%	-0.63%
1 Month Performance	-2.95%	-3.97%	-2.00%	-2.00%
1 Year Performance	N/A	27.39%	9.75%	13.62%

Synaptogenix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TAOX Synaptogenix	0.7063 of 5 stars	$3.29 -10.4%	N/A	N/A	$24.58M	$687.84K	N/A	4	Positive News
PLYX Polaryx Therapeutics	3.352 of 5 stars	$2.27 -0.4%	$8.50 +274.4%	N/A	$106.38M	N/A	N/A	11
FTLF FitLife Brands	4.425 of 5 stars	$11.04 -0.2%	$21.50 +94.8%	-22.8%	$103.62M	$81.46M	18.27	20	Positive News Gap Up
ALDX Aldeyra Therapeutics	3.6145 of 5 stars	$1.71 +0.9%	$5.50 +222.6%	-72.1%	$102.85M	N/A	N/A	10	Short Interest Decrease Gap Up
BDTX Black Diamond Therapeutics	3.6521 of 5 stars	$1.80 +0.3%	$9.83 +447.8%	-43.6%	$102.28M	$70M	N/A	90	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TAOX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Synaptogenix (TAOX) Competitors

TAOX vs. PLYX, FTLF, ALDX, BDTX, and ICCC

How does Synaptogenix compare to Polaryx Therapeutics?

Summary

How does Synaptogenix compare to FitLife Brands?

Summary

How does Synaptogenix compare to Aldeyra Therapeutics?

Summary

How does Synaptogenix compare to Black Diamond Therapeutics?

Summary

How does Synaptogenix compare to ImmuCell?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAOX vs. The Competition

Synaptogenix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Synaptogenix (TAOX) Competitors

TAOX vs. PLYX, FTLF, ALDX, BDTX, and ICCC

How does Synaptogenix compare to Polaryx Therapeutics?

Do institutionals and insiders hold more shares of PLYX or TAOX?

Is PLYX or TAOX more profitable?

Do analysts recommend PLYX or TAOX?

Which has stronger earnings & valuation, PLYX or TAOX?

Does the media refer more to PLYX or TAOX?

Summary

How does Synaptogenix compare to FitLife Brands?

Do analysts rate FTLF or TAOX?

Is FTLF or TAOX more profitable?

Does the media prefer FTLF or TAOX?

Which has more risk and volatility, FTLF or TAOX?

Which has stronger earnings & valuation, FTLF or TAOX?

Do insiders and institutionals have more ownership in FTLF or TAOX?

Summary

How does Synaptogenix compare to Aldeyra Therapeutics?

Which has more volatility and risk, ALDX or TAOX?

Is ALDX or TAOX more profitable?

Does the media refer more to ALDX or TAOX?

Do insiders and institutionals believe in ALDX or TAOX?

Do analysts prefer ALDX or TAOX?

Which has better earnings & valuation, ALDX or TAOX?

Summary

How does Synaptogenix compare to Black Diamond Therapeutics?

Which has more risk and volatility, TAOX or BDTX?

Does the media favor TAOX or BDTX?

Which has better valuation and earnings, TAOX or BDTX?

Do analysts prefer TAOX or BDTX?

Is TAOX or BDTX more profitable?

Do insiders & institutionals have more ownership in TAOX or BDTX?

Summary

How does Synaptogenix compare to ImmuCell?

Do insiders and institutionals believe in ICCC or TAOX?

Which has more volatility and risk, ICCC or TAOX?

Do analysts prefer ICCC or TAOX?

Is ICCC or TAOX more profitable?

Which has better valuation and earnings, ICCC or TAOX?

Does the media prefer ICCC or TAOX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAOX vs. The Competition

Synaptogenix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools